Finance

Lists
AORT:NYSE
Artivion Inc
$19.10
-1.44%
(-0.28) 1D
$19.10
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AORT...
Open
$19.62
High
$19.81
Low
$18.95
Mkt. cap
931.88M
Avg. vol.
709.50K
Volume
558.00K
52-wk high
$48.25
52-wk low
$18.95
EPS
-$0.36
Beta
1.31
Shares outstanding
48.79M
No. of employees
2K
Open
$19.62
High
$19.81
Low
$18.95
Mkt. cap
931.88M
Avg. vol.
709.50K
Volume
558.00K
52-wk high
$48.25
52-wk low
$18.95
EPS
-$0.36
Beta
1.31
Shares outstanding
48.79M
No. of employees
2K
News stories
From web sources and news partners
Profile
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Wikipedia
About Artivion Inc
CEOJames Patrick Mackin
Employees1.8K
Founded1984
HeadquartersKennesaw, Georgia, United States
SectorHealth Care
IndustryMedical device
Analyst ratings
Based on 5 analysts giving stock ratings to AORT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AORT in the last 3 months.
Highest
Current $19.10
$42.00 (+119.90%)
Average
$36.20 (+89.53%)
Lowest
$30.00 (+57.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Plovanic
Canaccord Genuity
Buy
Maintained
$30.00
+57.1%
11/06/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$38.00
+99%
11/06/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$40.00
+109.4%
11/06/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
$42.00
+119.9%
11/06/2026
Michael Sarcone
Jefferies
Buy
Initiated
$31.00
+62.3%
10/19/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Maintained
$39.20
+105.2%
08/07/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$45.00
+135.6%
08/07/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
$38.00
+99%
08/07/2026
Michael Matson
Needham
Buy
Reiterated
$44.00
+130.4%
08/07/2026
Eric Martinuzzi
Lake Street
Buy
Reiterated
$55.00
+188%
04/08/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.08 / $0.07
+21.21%beat
Revenue / Est. (USD)
123.79M / 117.20M
+5.62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
115.99M
116.34M
125.76M
123.79M
Cost of goods sold
42.85M
40.89M
45.24M
47.81M
Cost of revenue
42.85M
40.89M
45.24M
47.81M
Research and development expenses
9.12M
8.84M
9.06M
9.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54.64M
60.58M
60.13M
60.12M
Operating expense
63.76M
69.42M
69.18M
69.93M
Total operating expenses
106.61M
110.31M
114.42M
117.74M
Operating income
9.38M
6.03M
11.34M
6.05M
Other non operating income
1.18M
514.00K
-49.00K
149.00K
EBT including unusual items
6.54M
339.00K
-11.70M
-5.92M
EBT excluding unusual items
5.15M
579.00K
3.70M
-2.82M
Income tax expense
4.11M
-1.08M
1.81M
2.01M
Effective tax rate
62.89%
-317.99%
-15.48%
-33.89%
Other operating expenses
-
-
-
-
Net income
2.43M
1.42M
-13.51M
-7.93M
Net profit margin
2.09%
1.22%
-10.74%
-6.40%
Earnings per share
0.17
0.08
0.13
0.08
Interest and investment income
311.00K
205.00K
367.00K
102.00K
Interest expense
-5.62M
-5.37M
-7.25M
-8.52M
Net interest expenses
-5.31M
-5.16M
-6.89M
-8.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
15.14M
12.37M
18.08M
13.39M
Gain or loss from assets sale
-3.50M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps